Document Detail


Which antihypertensive drugs are the most nephroprotective and why?
MedLine Citation:
PMID:  20977400     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Hypertension is a major independent risk factor for kidney disease and for faster renal function loss. Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD).
AREAS COVERED IN THIS REVIEW: The present review focuses on the role of hypertension in the progression of chronic kidney disease (CKD), the renoprotective effects of different antihypertensive therapies, and the blood pressure levels that should be targeted in different patient populations. To this end, the PubMed (1975 - 2010) database was searched for English-language articles, using the following keywords: hypertension, kidney disease, ACE-inhibitor, angiotensin receptor blocker, aldosterone antagonist, renin inhibitor, proteinuria.
WHAT THE READER WILL GAIN: A comprehensive review of data on the association between hypertension and progression of chronic nephropathies and on the antihypertensive treatments with highest nephroprotective effects.
TAKE HOME MESSAGE: Blood pressure should be targeted to 140/90 mmHg or less in patients with hypertension but no renal injury and 130/80 mmHg or less in those with CKD. Amongst different antihypertensive drugs, renin angiotensin aldosterone system (RAAS) inhibitors have an incremental nephroprotective effect in proteinuric patients. Maximal RAAS inhibition should be aimed to optimize renoprotection in hypertensive patients with CKD and proteinuria.
Authors:
Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2651-63     Citation Subset:  IM    
Affiliation:
Mario Negri Institute of Pharmacological Research, Parco Scientifico Tecnologico Kilometro Rosso, Department of Medicine and Transplantation, Via Stezzano, 87, Ospedali Riuniti, 24126 Bergamo, Italy. gremuzzi@marionegri.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antihypertensive therapy and de-stiffening of the arteries.
Next Document:  Statins in patients with chronic kidney disease: why, who and when?